Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

World Congress of Bronchology and Interventional Pulmonology 2026

We are excited to announce that the World Congress of Bronchology and Interventional Pulmonology 2026 will be hosted by the Thoracic Society of Australia and New Zealand in the vibrant city of Melbourne, Australia. We are excited to announce that...

NextGen Pharma 2026

NextGen Pharma, a premier global forum dedicated to exploring the latest innovations, emerging technologies, and future-focused strategies in the pharmaceutical industry. NextGen Pharma, a premier global forum dedicated to exploring the latest...

2nd International Conference on Drug Discovery 2026

The 2nd International Conference on Drug Discovery 2026, organized by Scisynopsis Conferences, aims to bring together researchers, scientists, industry leaders, and academicians from around the world to explore groundbreaking innovations in drug...

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; Head Office: Chiyoda-ku, Tokyo; President: Shinro Nakamura; hereinafter referred to as "PHC") Life Science Division Biomedica Business Group (PHCbi) is pleased to announce that the MTR-OPC-OPC1-PW,...

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Parents looking for an infant formula made with whole milk now have a new option. Abbott announced the launch of Similac® 360 Total Care Made With Whole Milk—the first and only commercially sterile, ready-to-feed liquid infant formula made with...

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people...

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive...

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans...

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

BioVigil, the market leader in automated hand hygiene and infection prevention technology, announced that it has recorded more than 1 billion hand hygiene opportunities (HHOs) since the company’s founding in 2012. This milestone reflects the...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Triquetra Health, a clinical-grade supplement company specializing in evidence-based formulation, announced the launch of BioActive Vitamin B1™ Clinical Strength, a complete B1 activation system delivering 600mg benfotiamine at the...

Dallas-Based Microbiome Brand resbiotic® Comes Home to Texas with Launch at H-E-B

Today, resbiotic® the physician-developed microbiome health company headquartered in Dallas, Texas, announced the launch of two of its science-backed microbiome formulas — resB® Lung Support Probiotic and resG prebeet® Prebiotic — at H-E-B stores...

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to...

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full approval in children with achondroplasia. . "This...

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis to reduce the frequency of bleeding episodes in pediatric patients...

Industry Veteran Marie Emms Appointed President of Clinical Business at Spectrum Science

Spectrum Science, an independent, full-service, strategic platform offering integrated clinical, commercial, and communications services, announced the appointment of Marie Emms as President of its clinical trial recruitment and retention...

Cannabix Technologies and Omega Laboratories Announce a DOT-Like Breath-Based Drug Testing Panel for Recent-Use Detection

Omega Laboratories, Inc. ("Omega"), and Cannabix Technologies Inc. announce the development and validation of a DOT-like drug-test panel for breath testing. The validated laboratory method expands Omega's breath-testing capability beyond...

Organon to Present New Analysis of VTAMA® (tapinarof) Cream, 1%

Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced that a new analysis of Phase 3 data evaluating VTAMA cream. The presentation includes a pooled post hoc analysis...

European Commission Approves AbbVie's TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R)...